Innospec Inc.
NASDAQ:IOSPChemicals - Specialty
+$0.08 today
- Market cap
- $1.94B
- Beta
- 0.91
- P/E (TTM)
- 18.0
- EPS (TTM)
- $4.61
- Dividend yield
- 2.15%
Volume 0.23M
Average 0.24M
IOSP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Innospec Inc.NASDAQ: IOSP
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows in line with its trailing trend
Q2 FY2026 research & development of $14.2M rose 4.4% year over year, in line with the +4.0% change in trailing-twelve-month research & development. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.
Context
- Research & development amounted to 2.9% of revenue in FY2025, up 0.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.4% holds above the trailing-twelve-month pace of +4.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 51M USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +8.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51M | +6.7% |
| FY2024 | 2024-12-31 | 47.8M | +14.6% |
| FY2023 | 2023-12-31 | 41.7M | +7.8% |
| FY2022 | 2022-12-31 | 38.7M | +3.5% |
| FY2021 | 2021-12-31 | 37.4M | — |
Research & Development vs competitors
How IOSP compares with its peers on the latest reported figures
- IOSP's LTM Jun 2026 research & development of $52.1M is the 5th highest of the 10 companies compared; the peer median is $3.32M.
- Its year-over-year change of +4.0% is the highest of 7, against a peer median of -8.5%.
- Research & development amounts to 2.8% of revenue for IOSP, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $246M | -7.2% | -1.1% | 2.8% | |
| LTM Jun 2026 | $128.57M | -1.5% | -2.0% | 4.7% | |
| LTM Jun 2026 | $55M | -9.8% | +2.4% | 1.5% | |
| LTM Jun 2026 | $55M | +3.8% | -0.6% | 3.0% | |
| LTM Jun 2026 | $52.1M | +4.0% | +9.6% | 2.8% | |
| LTM Mar 2026 | $3.32M | -26.0% | +4.2% | 3.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Aug 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding IOSP) | $3.32M | -8.5% | -0.6% | 1.5% | |
Competitors are the stored peer set for IOSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48B | 1.96B | 1.95B | 1.85B | 1.78B |
| Cost of Revenue | 1.05B | 1.38B | 1.36B | 1.3B | 1.29B |
| Gross Profit | 434.9M | 586.7M | 591.1M | 542.9M | 492.4M |
| Gross Margin | 29.3% | 29.9% | 30.3% | 29.4% | 27.7% |
| Research & Development | 37.4M | 38.7M | 41.7M | 47.8M | 51M |
| Selling, General & Admin | 267.2M | 360.7M | 387.8M | 314M | 285.1M |
| Operating Expenses | 302.8M | 399.4M | 429.5M | 365M | 336.1M |
| Depreciation & Amortization | 42.7M | 40.1M | 39.3M | 43.5M | 43.6M |
| EBITDA | 173M | 225.8M | 213.7M | 224.6M | 181.7M |
| EBITDA Margin | 11.7% | 11.5% | 11.0% | 12.2% | 10.2% |
| Operating Income | 132.1M | 187.3M | 161.6M | 177.9M | 156.3M |
| Operating Margin | 8.9% | 9.5% | 8.3% | 9.6% | 8.8% |
| Interest Income | 0 | 0 | 0 | 0 | 9.2M |
| Interest Expense | 1.5M | 1.1M | 0 | 0 | 0 |
| Other Income / Expenses | 2.3M | (2.7M) | 12.8M | (136.7M) | (18.2M) |
| Income Before Tax | 134.4M | 184.6M | 174.4M | 41.2M | 138.1M |
| Pre-Tax Margin | 9.1% | 9.4% | 8.9% | 2.2% | 7.8% |
| Income Tax Expense | 41.3M | 51.6M | 35.3M | 5.6M | 21.5M |
| Net Income | 93.1M | 133M | 139.1M | 35.6M | 116.6M |
| Net Margin | 6.3% | 6.8% | 7.1% | 1.9% | 6.6% |
| EPS (Basic) | 3.78 | 5.37 | 5.60 | 1.43 | 4.69 |
| EPS (Diluted) | 3.75 | 5.32 | 5.56 | 1.42 | 4.67 |
| Weighted Avg Shares | 24.65M | 24.79M | 24.85M | 24.93M | 24.88M |
| Weighted Avg Shares (Diluted) | 24.85M | 24.98M | 25.02M | 25.12M | 24.99M |
Innospec Inc.
NASDAQ:IOSP
Intrinsic Alpha fair value
Locked
Current Price
$78.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.